125 related articles for article (PubMed ID: 9872339)
1. Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females.
Lee Y; Ermlich SJ; Sterrett AT; Goldberg MR; Blum RA; Brucker MJ; McLoughlin DA; Olah TV; Zhao J; Rogers JD
Biopharm Drug Dispos; 1998 Dec; 19(9):577-81. PubMed ID: 9872339
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers.
Lee Y; Conroy JA; Stepanavage ME; Mendel CM; Somers G; McLoughlin DA; Olah TV; De Smet M; Keymeulen B; Rogers JD
Br J Clin Pharmacol; 1999 Apr; 47(4):373-8. PubMed ID: 10233200
[TBL] [Abstract][Full Text] [Related]
3. Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects.
Goldberg MR; Lee Y; Vyas KP; Slaughter DE; Panebianco D; Ermlich SJ; Shadle CR; Brucker MJ; McLoughlin DA; Olah TV
J Clin Pharmacol; 2000 Jan; 40(1):74-83. PubMed ID: 10631625
[TBL] [Abstract][Full Text] [Related]
4. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans.
Vyas KP; Halpin RA; Geer LA; Ellis JD; Liu L; Cheng H; Chavez-Eng C; Matuszewski BK; Varga SL; Guiblin AR; Rogers JD
Drug Metab Dispos; 2000 Jan; 28(1):89-95. PubMed ID: 10611145
[TBL] [Abstract][Full Text] [Related]
5. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and food interaction of MK-462 in healthy males.
Cheng H; Polvino WJ; Sciberras D; Yogendran L; Cerchio KA; Christie K; Olah TV; McLoughlin D; James I; Rogers JD
Biopharm Drug Dispos; 1996 Jan; 17(1):17-24. PubMed ID: 8991488
[TBL] [Abstract][Full Text] [Related]
7. Rizatriptan: a review of its efficacy in the management of migraine.
Dooley M; Faulds D
Drugs; 1999 Oct; 58(4):699-723. PubMed ID: 10551439
[TBL] [Abstract][Full Text] [Related]
8. Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist.
Sciberras DG; Polvino WJ; Gertz BJ; Cheng H; Stepanavage M; Wittreich J; Olah T; Edwards M; Mant T
Br J Clin Pharmacol; 1997 Jan; 43(1):49-54. PubMed ID: 9056052
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of rizatriptan in healthy elderly subjects.
Musson DG; Birk KL; Panebianco DL; Gagliano KD; Rogers JD; Goldberg MR
Int J Clin Pharmacol Ther; 2001 Oct; 39(10):447-52. PubMed ID: 11680669
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study.
Fraser IP; Han L; Han TH; Li CC; Hreniuk D; Stoch SA; Wagner JA; Linder S; Winner P
Headache; 2012 Apr; 52(4):625-35. PubMed ID: 22289113
[TBL] [Abstract][Full Text] [Related]
11. Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol.
Goldberg MR; Sciberras D; De Smet M; Lowry R; Tomasko L; Lee Y; Olah TV; Zhao J; Vyas KP; Halpin R; Kari PH; James I
Br J Clin Pharmacol; 2001 Jul; 52(1):69-76. PubMed ID: 11453892
[TBL] [Abstract][Full Text] [Related]
12. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine.
Goldberg MR; Lowry RC; Musson DG; Birk KL; Fisher A; De Puy ME; Shadle CR
J Clin Pharmacol; 1999 Feb; 39(2):192-9. PubMed ID: 11563413
[TBL] [Abstract][Full Text] [Related]
13. Rizatriptan: an update of its use in the management of migraine.
Wellington K; Plosker GL
Drugs; 2002; 62(10):1539-74. PubMed ID: 12093318
[TBL] [Abstract][Full Text] [Related]
14. CNS effects of sumatriptan and rizatriptan in healthy female volunteers.
van der Post J; Schram MT; Schoemaker RC; Pieters MS; Fuseau E; Pereira A; Baggen S; Cohen AF; van Gerven JM
Cephalalgia; 2002 May; 22(4):271-81. PubMed ID: 12100089
[TBL] [Abstract][Full Text] [Related]
15. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.
Christie S; Göbel H; Mateos V; Allen C; Vrijens F; Shivaprakash M;
Eur Neurol; 2003; 49(1):20-9. PubMed ID: 12464714
[TBL] [Abstract][Full Text] [Related]
16. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group.
Visser WH; Terwindt GM; Reines SA; Jiang K; Lines CR; Ferrari MD
Arch Neurol; 1996 Nov; 53(11):1132-7. PubMed ID: 8912486
[TBL] [Abstract][Full Text] [Related]
17. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group.
Teall J; Tuchman M; Cutler N; Gross M; Willoughby E; Smith B; Jiang K; Reines S; Block G
Headache; 1998 Apr; 38(4):281-7. PubMed ID: 9595867
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine.
Gijsman H; Kramer MS; Sargent J; Tuchman M; Matzura-Wolfe D; Polis A; Teall J; Block G; Ferrari MD
Cephalalgia; 1997 Oct; 17(6):647-51. PubMed ID: 9350384
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers.
Shadle CR; Liu G; Goldberg MR
J Clin Pharmacol; 2000 Mar; 40(3):309-15. PubMed ID: 10709161
[TBL] [Abstract][Full Text] [Related]
20. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group.
Kramer MS; Matzura-Wolfe D; Polis A; Getson A; Amaraneni PG; Solbach MP; McHugh W; Feighner J; Silberstein S; Reines SA
Neurology; 1998 Sep; 51(3):773-81. PubMed ID: 9748025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
